Pressure BioSciences (PBIO), One of the Most Undervalued Biotech Companies

RELATED QUOTES

SymbolPriceChange
PBIO0.400.0000

Pressure BioSciences (PBIO), One of the Most Undervalued Biotech Companies

By Grant Zeng, CFA
 

Pressure BioSciences (PBIO) is a research products and services provider for the life science industry. The Company’s novel, enabling platform technology pressure cycling technology (:PCT) has competitive advantages over existing technologies in the sample preparation market. PCT is being increasingly recognized by research labs and user adoption will accelerate in the coming years due to the focused marketing efforts by the Company.

However, the Company is one of the most undervalued biotech companies in our view. Our call is based on two major factors: financial results and business development are improving and valuation is very attractive.

To read our full research report on Pressure Bio, download it here: PBIO Upgrade to Outperform 11-29-12

Record PCT Sales Reported for 3Q12    

On Nov 15, 2012, Pressure BioSciences (PBIO) announced financial results for the three month period ended September 30, 2012.

Total revenue for the third quarter of 2012 was $391,616 compared to $280,422 for the comparable period in 2011, a 40% increase. 

Revenue from the sale of Pressure Cycling Technology (:PCT) products and services was $297,867 for the third quarter of 2012 compared to $217,734 for the same period in 2011, a 37% increase. Grant revenue in the third quarter of 2012 was $93,749 compared to $62,688 for the same period in the prior year. 

The Company installed eight PCT Sample Preparation Systems (PCT Systems) during both quarters. Sales of PCT-based consumables generated revenue of approximately $28,000 for the three months ended September 30, 2012 compared to approximately $21,000 for the same period in 2011, an increase of 33%.

Operating loss for the third quarter of 2012 was $686,520, compared to $745,811 for the same period in 2011, a decrease of approximately 8%. After the exclusion of non-cash charges, operating cash burn for the 2012 third quarter was approximately $507,000 compared to approximately $658,000 for the third quarter of 2011, a decrease of approximately 23%. 

Loss per common share - basic and diluted - was $0.09 for the third quarter of 2012 compared to $0.19 for the same period in 2011. 

Third quarter of 2012 was an impressive quarter.  PBIO’s financial results continued to improve. 

PBIO recorded record PCT product sales of $0.30 million in 3Q12, an increase of 37% year over year. Third quarter product sales was also $0.05 million over our estimate of $0.25 million. PBIO also reported that revenue for the first nine months of 2012 exceeded $1.00 million, which surpassed the total revenue for 2011.

For the third quarter of 2012, the Company worked hard to increase revenue while reducing its operating loss. Operating loss for the third quarter of 2012 was $686,520, a decrease of approximately 8% year over year. Operating loss also beat our estimate of $0.9 million.

We are especially happy to see increased sales of consumables for the quarter. Sales of PCT-based consumables generated revenue of approximately $28,000 for the three months ended September 30, 2012 compared to approximately $21,000 for the same period in 2011, an increase of 33%. We expect the sales of consumables will continue to grow in the coming quarters. As we pointed before, this growth in consumables sales is very important to the Company’s long term sustainable growth. We remind investors consumables are recurring revenue source to the Company with higher margin, which are associated with the installation of PCT equipments. When more and more equipments are installed, more consumables will be used. The growth of installed equipments will eventually stabilize, but the use of consumables will increase each quarter as the equipment base becomes larger. Although revenue from consumables currently accounts for only a small portion of PCT product sales (about 10%), this number will become larger going forward and make a meaningful contribution to the top line.

Balance Sheet Boosted with the Conversion of Ironridge BioPharma Convertibles

On November 28, 2012, PBIO announced that Ironridge BioPharma Co. has converted their remaining 200 shares of the Company's Series E Convertible Preferred Stock into shares of the Company's common stock.  Following this conversion, all 500 shares of Series E Preferred Stock purchased by Ironridge in the April 2012 $500,000 registered direct transaction with the Company have been converted.  

The total number of shares of common stock issued to Ironridge for their Series E Preferred Stock investment was 1,113,033, of which 688,378 were reflected in the 11,189,612 shares issued and outstanding on September 30, 2012.  In connection with the Series E Preferred Stock transaction, the Company paid the make-whole dividend with a combination of cash and common stock.

Ironridge BioPharma Co. is an institutional investor specializing in equity investments in the life sciences sector.  Ironridge is a long-only institutional investor that seeks to be a long-term financial partner. Ironridge made the investment in PBIO this past April. The funds received were used in part to support the new marketing and sales program that PBIO introduced earlier this year, which helped PBIO achieve record PCT products revenue in the third quarter of 2012, and will also play an important role in PBIO’s  anticipated future revenue growth. 

With the conversion, the perceived “overhang” is gone, and PBIO paid out no more shares than originally registered. The conversion not only boosts PBIO’s balance sheet, but also validates the Company’s PCT technology platform.  This is an indication that Ironridge BioPharma is optimistic about PBIO’s prospect and is willing to become its long term investor. 

Two Big Distribution Deals will Boost Product Sales in 4Q12 and Beyond

On November 26, 2012, PBIO announced that it has signed deal with British Constant Systems Ltd (CS). The two companies have entered into a two-way, strategic marketing, selling, and distribution agreement. 

Under the terms of the Agreement, PBIO has been awarded non-exclusive rights to market, sell, and distribute CS's unique, high-pressure cell disruption equipment and consumables in the United States, Canada, and Mexico.  Meanwhile, CS has been awarded the rights to market, sell, and distribute PBIO's pressure cycling technology (:PCT) based instruments and consumables in England, Scotland, Wales, Ireland, Spain, Portugal, Italy, Norway, Sweden, Finland, Denmark, and Singapore.  CS currently has strong sales and distribution channels in all twelve of these countries. PBIO, on the other hand, has none.  The Agreement is in effect until December 31, 2013; however, PBIO and CS expect to extend the Agreement prior to its termination.

This is a big deal for PBIO in our view. The two companies are worldwide leaders of complementary ultra-high pressure product lines for the life sciences market. Constant Systems is a British company that has been providing niche biomedical products and services to a global client base since 1989. 

The two product lines complement each other exceedingly well. While both the CS and PBIO technologies are based on high pressure, each product line has fundamental scientific capabilities that the other does not have.  PBIO's PCT Platform uses certain patented pressure mechanisms to achieve small-scale, molecular level effects.  CS's technology uses different, proprietary pressure mechanisms for larger-scale, non-molecular level processing.  In a number of routine laboratory applications, such as protein extraction, both effects can be critical to success. Therefore, for protein extraction and a number of other important scientific applications, laboratories will benefit by using the CS and PBIO products, either separately or together. This is a wonderful synergy of two well-respected, growing, and complementary product lines.

Constant Systems’ reach will introduce PBIO’s PCT products into 12 countries where PBIO does not have current coverage. Equally important, CS’ pressure-based cell disruption systems are needed by many of the same companies and scientists in North America that use or need PBIO’s PCT. Therefore, revenue for PBIO could be boosted in two ways in 2013 and beyond.

On November 7, 2012, PBIO and Cole-Parmer signed a supplier agreement. Under the agreement, Cole-Parmer will distribute PBIO’s Shredder SG3™ System.

Cole-Parmer is a leading global source of laboratory and industrial fluid handling products, instrumentation, equipment, and supplies since 1955. Its product lines, including popular brand names such as Masterflex®, Oakton®, and more, are sold through company-owned customer channel outlets and a strong network of international dealers.

With Cole-Parmer’s reputation and extensive distribution channels, sales of SG3 will be greatly boosted in the coming quarters, which will make a meaningful contribution to PBIO’s top line growth down the road. 

PCT Platform Continues to Show Advantages in Multiple Studies

Recently, PBIO announced that multiple research reports have cited the ability of the Company’s PCT Platform to improve the detection of RNA, DNA, and/or protein in forensic, environmental, and biodefense applications, and in research studies focused on the discovery of biomarkers of disease. These studies were conducted in laboratories worldwide, including:

  •     On Nov 2, 2012, PBIO announced that scientists from two separate research groups presented data at the recent HUPO 11th Annual World Congress (Boston, MA) indicating that the incorporation of the Company’s PCT Platform into their sample preparation processes resulted in a marked improvement in the quality and/or efficiency of test results. These studies were presented by scientists from the Center for Biologics Evaluation and Research of the FDA and from Janssen Research and Development.

 

  •    On Nov 14, 2012, PBIO announced that Dr. Bradford Powell, a prominent microbiologist and recognized infectious diseases expert, presented a keynote address during the opening ceremony of this year’s annual Clinical Microbiology & Microbial Genomics Conference (ClinMicro-2012). In the Keynote address and a second, main session presentation in the conference, Dr. Powell presented data highlighting the advantages of the Company’s powerful and patented PCT Platform that have been shown to enable significant improvements in molecular-based microbiological testing, a rapidly growing and extremely important area in laboratory medicine today.

 

  •    On Oct 18, 2012, PBIO announced that two research groups have reported on the ability of the Company’s PCT Platform to improve the detection of DNA in challenging forensic samples. The studies were presented by scientists from the Institute of Applied Genetics, Department of Forensic and Investigative Genetics, University of North Texas Health Science Center (:UNTHSC) in Fort Worth Texas, and from the Harris County Institute of Forensic Sciences in Houston Texas. The study results were presented at the 23rd annual International Symposium on Human Identification (ISHI), being held from October 15-18, 2012, in Nashville, TN.

We believe these findings, together with previous publications, strongly support the importance of the PCT Platform in the life sciences field, including forensics, environmental analyses, biodefense, and biomarker discovery applications. This has created increased interest in its PCT Platform in the past, and will continue to drive sales in the future.

In terms of valuation, we think PBIO shares are undervalued based on the Company’s fundaments. Currently, the Company trades around $0.20 per share with a market cap of $2.0 million. We believe this deeply undervalues the Company based on the current fundamentals mentioned above. We understand that market discounts the value of the Company because the Company has only limited revenue base and has been losing money since its inception. We also understand that the Company has a relatively weak balance sheet, and further financing will be needed soon. However, when we look at the Company and the industry in which it operates in more detail, we realize that this is a company with huge opportunity and one that can grow its revenue and earnings at a tremendous rate in the next few years.

We are now optimistic about the Company’s prospect. With a rapidly growing market worldwide, combined with its unique technology and broad range of product offering, the Company is well positioned to boost its top line and bottom line in the coming years.

We think PBIO is more like a development stage biotech company. Our price target of $1.25 per share represents a market cap of about $14 million.  As long as the Company can execute its growth strategy correctly, we believe this goal is achievable.
 

For additional research on small-cap stocks, please visit scr.zacks.com.

To become a subscriber to Zacks SCR and receive SCR blogs and research reports emailed directly to your inbox, please visit our Subscribe page.

Read the Full Research Report on PBIO

Zacks Investment Research



More From Zacks.com

--

Get stories like this on the Yahoo app and discover more every day.
Download it now.
Loading...
  • US stocks flat as oil shares pressured AFP - 3 minutes 57 seconds ago

    Petroleum-linked shares retreated Wednesday ahead of a US oil inventory report as Wall Street stocks opened little-changed in sluggish trade. Shares of Dow members ExxonMobil and Chevron dipped with oil ... … More »

  • Markets Right Now: US stocks open lower Associated Press - 4 minutes 41 seconds ago

    The latest on developments in global financial markets (all times local): 9:35 a.m. Stocks are opening slightly lower on Wall Street as the market gives back a modest gain from the day before. Mining and ... … More »

  • Wall Street opens little changed as investors eye Fed
    Wall Street opens little changed as investors eye Fed Reuters - 14 minutes ago

    REUTERS - U.S. stocks were little changed at the open on Wednesday as investors kept up their wait for Federal Reserve Chair Janet Yellen's speech on Friday for clues on the timing of an interest rate ... … More »

  • Iran yet to decide on OPEC limits: ministry source AFP - 25 minutes ago

    Iran has yet to take any decision on whether to set a ceiling on oil production or take part in a planned OPEC meeting in Algeria, an oil ministry source told AFP Wednesday. "It is too early to talk ... … More »

  • Cnooc Posts 1st Half-Year Loss on Canadian Oil Sands Charge (3) Bloomberg - 49 minutes ago

    Prices have whipsawed this year, flipping five times between bear and bull markets, as production from nations outside the Organization of Petroleum Exporting Countries, including China and the U.S., declines in the wake of a price crash that began … More »

  • EU warns Greece statistics row 'dangerous' for bailout Reuters - 1 hour 14 minutes ago

    BRUSSELS/ATHENS (Reuters) - The European Union called on Greece on Wednesday to quash what Brussels said were false accusations the Greek statistics agency rigged data to help foreign creditors and warned that the row posed risks to Athens' current … More »

  • Glencore’s Worst Profit Shows Miners Still Reeling From Crisis Bloomberg - 1 hour 15 minutes ago

    Weak raw-material prices caused profit at the commodities giant to plunge 66 percent in the first half to $300 million. The shares slumped as much as 6 percent in London, the most in two months, even as Glencore promised to cut debt even further … More »

  • New trade deal with Britain may take time, Norwegian minister says Reuters - 1 hour 38 minutes ago

    Norway wants to maintain a good relationship with Britain after it leaves the European Union but it may take a long time for a new trade agreement to be established, the EU affairs minister in Oslo said on Wednesday. Elisabeth Aspaker told a … More »

  • Qatari state fund buys stake in NY's Empire State Building
    Qatari state fund buys stake in NY's Empire State Building Associated Press - 1 hour 40 minutes ago

    Qatar's sovereign wealth fund has made an iconic purchase in America — a stake in the company that owns New York's Empire State Building. The $622-million purchase by the Qatar Investment Authority comes ... … More »

  • European stocks rebound as euro slips, U.S. curve flattens
    European stocks rebound as euro slips, U.S. curve flattens Reuters - 1 hour 44 minutes ago

    European stocks edged towards consecutive daily gains for the first time in three weeks on Wednesday, drawing support from a weak euro as investors moved to price in a U.S. interest rate rise, boosting the dollar. The earlier mood was more … More »

  • WPP sees signs of post-Brexit recovery in British ad market
    WPP sees signs of post-Brexit recovery in British ad market Reuters - 1 hour 47 minutes ago

    WPP (WPP.L), the world's largest advertising group, reported a better than expected jump in first-half net sales and said its British operations showed signs in July of a "post-Brexit recovery", sending its shares to a record high. Run by … More »

  • Gold steady as investors await U.S. rate clues
    Gold steady as investors await U.S. rate clues Reuters - 1 hour 48 minutes ago

    Gold held steady on Wednesday as investors took to the sidelines ahead of a speech by Federal Reserve Chair Janet Yellen this weekend which will be closely watched for further clues on U.S. interest rate policy. Yellen is scheduled to address a … More »

  • Exclusive - German ratings firm Scope seeks ECB recognition Reuters - 1 hour 48 minutes ago

    German rating firm Scope says it is in talks to become one of the European Central Bank's recognised sovereign credit agencies, though tough requirements mean the process could take at least three years. Scope would become the first agency based in … More »

  • Oil prices drop as market tracks US supplies AFP - 1 hour 49 minutes ago

    Oil prices fell Wednesday, with Brent stuck below $50, after data showed an increase in US crude stockpiles, adding to supply glut concerns. Data from the American Petroleum Institute (API) Tuesday showed ... … More »

  • U.S. oil falls 2 percent on surprise build in crude stocks
    U.S. oil falls 2 percent on surprise build in crude stocks Reuters - 1 hour 52 minutes ago

    U.S. oil prices fell more than 2 percent on Wednesday on an unexpected increase in U.S. crude stocks that revived worries about the supply glut that has capped prices for the past two years. Industry data from the American Petroleum Institute (API) … More »

  • U.S. oil falls 2 pct on surprise build in crude stocks
    U.S. oil falls 2 pct on surprise build in crude stocks Reuters - 1 hour 59 minutes ago

    U.S. oil prices fell more than 2 percent on Wednesday on an unexpected increase in U.S. crude stocks that revived worries about the supply glut that has capped prices for the past two years. Industry data from the American Petroleum Institute (API) … More »

  • Buba's Dombret says eyes LSE-Deutsche Boerse merger with some concern Reuters - 2 hours 18 minutes ago

    Bundesbank board member Andreas Dombret said he was concerned the planned $29 billion (21.89 billion pounds) merger between German exchange operator Deutsche Boerse and the London Stock Exchange may raise systemic risks in derivatives clearing. … More »

  • PetroChina profit almost wiped out in first half
    PetroChina profit almost wiped out in first half AFP News - 2 hours 23 minutes ago

    China’s biggest oil producer PetroChina's net profit plunged 97.9 percent in the first half of this year, it said Wednesday, as it struggled with a weak domestic economy and low oil prices. Net profit was 531 million yuan ($79.9 million) in the … More »

  • European equities mainly rise on German GDP
    European equities mainly rise on German GDP AFP News - 2 hours 25 minutes ago

    European stock markets mostly rose on Wednesday, shrugging off a largely downbeat session in Asia, with sentiment partly lifted by German economic growth data. Strong foreign trade and buoyant consumption drove Germany's economy, Europe's largest, … More »

  • Malaysian oil service provider Perisai in talks with bondholders Reuters - 2 hours 32 minutes ago

    Malaysian oil and gas service provider Perisai Petroleum Teknologi on Wednesday said it has started talks with holders of its S$125 million ($92.36 million) bond maturing on Oct. 3. Perisai said its interest cover ratio had fallen below the … More »

  • Angry Birds maker Rovio turns a profit, plans movie sequel
    Angry Birds maker Rovio turns a profit, plans movie sequel Reuters - 2 hours 33 minutes ago

    Finnish mobile game and animation maker Rovio Entertainment Ltd said on Wednesday it made a profit in the first half of the year and was planning a sequel to its successful Angry Birds Movie. Rovio's adjusted operating profit in the first six … More »

  • Philippines' Duterte says willing to allow online gambling resumption Reuters - 2 hours 35 minutes ago

    Philippine President Rodrigo Duterte said on Wednesday he's willing to allow a resumption of online gambling in the Southeast Asian nation if correct taxes are paid and gaming parlours are far from schools and churches. The new president added … More »

  • German banks right to charge for accounts - Bundesbank's Dombret Reuters - 2 hours 44 minutes ago

    German banks are right to consider current account fees to counter low central bank rates, but an outright charge on deposits, as pioneered by a few lenders, is unlikely to become common, Bundesbank board member Andreas Dombret told Reuters. While … More »

  • EU, Portugal agree on recapitalisation for bank CGD Reuters - 2 hours 57 minutes ago

    The European Commission said it had reached an agreement in principle with Portugal over the recapitalisation on market terms of Portuguese state-owned bank Caixa Geral de Depositos - the country's largest lender. Under the terms of the deal, … More »

  • EU says Greek debt statistics not manipulated in 2010-2015
    EU says Greek debt statistics not manipulated in 2010-2015 Reuters - 3 hours ago

    The European Union's Employment Commissioner Marianne Thyssen said on Wednesday the Greek statistics office did not manipulate data on the country's debt in 2010-2015 and that she had sent a letter to Athens asking it to refute any such suggestions. … More »

 
Recent Quotes
Symbol Price Change % Chg 
Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.
You need to enable your browser cookies to view your most recent quotes.
 
Sign-in to view quotes in your portfolios.

MARKET MOVERS

  • Most Actives
    Most Actives
    NamePriceChange% Chg
    0.1290.0000.00%
    N21.SI
    0.250.00-1.96%
    5ME.SI
    0.60+0.04+6.57%
    5TP.SI
    0.99-0.02-1.98%
    Y92.SI
    0.156+0.007+4.70%
    AFC.SI
  • % Gainers
    % Gainers
    NamePriceChange% Chg
    0.30+0.06+22.45%
    T18.SI
    0.15+0.02+15.38%
    5TI.SI
    0.225+0.025+12.50%
    Y35.SI
    0.51+0.05+12.09%
    BHU.SI
    0.162+0.017+11.72%
    QS9.SI
  • % Losers
    % Losers
    NamePriceChange% Chg
    0.011-0.115-91.27%
    QF6.SI
    0.23-0.17-42.50%
    AWI.SI
    0.205-0.055-21.15%
    I06.SI
    0.45-0.10-18.18%
    BFK.SI
    0.385-0.085-18.09%
    E8Z.SI

Market Data

  • Currencies
    Currencies
    NamePriceChange% Chg
    1.3539+0.0027+0.20%
    USDSGD=X
    1.5257-0.0013-0.09%
    EURSGD=X
    1.7939+0.0112+0.63%
    GBPSGD=X
    74.1130+0.004+0.01%
    SGDJPY=X
    5.7244-0.0111-0.19%
    SGDHKD=X
    2.9829+0.0071+0.24%
    SGDMYR=X
    9,784.7578-31.9463-0.33%
    SGDIDR=X
    4.9148+0.0014+0.03%
    SGDCNY=X
    1.0326+0.0037+0.36%
    AUDSGD=X
  • Commodities
    Commodities
    NamePriceChange% Chg
    1,332.50-13.60-1.01%
    GCZ16.CMX
    18.65-0.28-1.46%
    SIU16.CMX
    101.29-2.61-2.51%
    ^XAU
    2.10-0.02-0.78%
    HGU16.CMX
    47.55-0.55-1.14%
    CLV16.NYM
  • Bonds
    Bonds
    TreasuryYield (%)Yield Change
    1.13-0.02
    ^FVX
    1.54-0.01
    ^TNX
    2.23-0.01
    ^TYX